Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILP with Melphalan for Advanced Extremity Melanoma or Sarcoma
NCT02507076Withdrawn
- Sponsor
- Albert Einstein College of Medicine
- Start
- Apr 2012
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of melphalan in melanoma, sarcoma, Merkel cell carcinoma (MCC) and 2 more, sponsored by Albert Einstein College of Medicine. Primary endpoint: Overall Response Rate at 12 weeks. Planned start Apr 2012; status: withdrawn.
02
Drugs
melphalan
03
Conditions
melanomasarcomaMerkel cell carcinoma (MCC)basal cell carcinoma (BCC)squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT02507076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02507076.